麦科田拟港股上市 中国证监会要求补充说明公司辅导备案情况等

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Shenzhen Maikedian Biomedical Technology Co., Ltd. to provide supplementary materials regarding its overseas listing application, including details on its A-share listing plans and any significant impacts on the issuance process [1][3]. Group 1: Company Financial and Operational Details - The CSRC requires Maikedian to clarify its past capital increases, decreases, and share transfer pricing, including whether actual contributions were made and if there are any issues with capital obligations [1][2]. - The company must provide information on its subsidiaries' business scope, including e-commerce, medical research, and testing services, and confirm whether it has obtained necessary qualifications [1][3]. - Maikedian is asked to detail the types of in vitro diagnostic products it offers, particularly those related to human stem cells and gene diagnosis and treatment technologies [1][3]. Group 2: Shareholder and Regulatory Compliance - The CSRC requests clarification on the basic situation of major shareholders, particularly foreign enterprises and Hong Kong companies, to ensure compliance with legal regulations [2]. - The company must explain the progress of state-owned shareholders in fulfilling state asset management procedures [3]. - Maikedian is required to disclose the shareholding structure before and after the full exercise of the over-allotment option, particularly regarding domestic shares and H-shares [3]. Group 3: Listing Plans and Market Presence - The company needs to provide an update on its counseling record and plans for continuing the A-share listing process, including any factors that may significantly affect the listing [3][4]. - The prospectus indicates that Maikedian offers a comprehensive product portfolio that meets clinical needs across various healthcare settings, with over 50 life-support products, 80 minimally invasive products, and 210 in vitro diagnostic products commercialized as of June 30, 2025 [4]. - Maikedian's products are distributed in over 140 countries and regions, covering more than 6,000 hospitals in China, including approximately 90% of top-tier hospitals [4].